ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
EGFR agonists support the protective effect of Langerhans against UV-induced damage of skin cells, a hallmark of lupus erythematosus and other autoimmune and dermatologic conditions, a team of US and German researchers report.
A team of Scots, Belgian and Spanish researchers claim they have found a target to prevent failure of liver regeneration following intoxination or acute injury.
London-headquartered gene therapy Orchard Therapeutics has closed a US-$150m series C financing round to push MAAs and BLAs of three late-stage gene therapies by 2021.
Life Sciences Partners and Andera Partners together with Pfizer Ventures and Novartis Venture Fund have put €85m into the cancer drug development company Artios Pharma Ltd.
German neurogenetics at the Max-Planck-Institute for Experimental Medicine have cured the rare incurable hereditary Charcot-Marie-Tooth disease by simply supplementing the food of mice carrying the disease-causing duplication of the PMP22 gene with lecithin. The phospholipid supplementation enabled Schwann cells deficient in lipid synthesis to restore the insulating myelin sheet around peripheral neurons which is needed to speed up neuronal transmission.
Biological Industries (BI) develops, manufactures, packs, and supplies cell culture products for academic research, diagnostic labs, hospitals, and the biotechnology and biopharmaceutical industries. BI specialises in serum-free, xeno-free, animal component-free media, as well as contract manufacturing services that range from raw material supply, through labeling and packaging, to ready-to-market product.
German researchers have found a molecular switch that determines whether mesenchymal fibroblasts differentiate into fat- or bone-forming cells opening the avenue to modulation of the processes.
Researchers at Roche’s US arms Genentech and Foundation Medicine Inc. (FMI) presented a liquid biopsy test that can be used to identify NSCLC patients who respond to Roche’s PD-L1 blocker Tecentriq earlier than to FMI’s tissue based tumour mutation burden (TMB) assay.
German pharma company and CDMO Boehringer Ingelheim (BI) steps into the lucrative field of gene therapy. Together with the UK Cystic Fibrosis Gene Therapy Consortium (GTC), BI aims at developing replacement therapies compensating for mutations that lead to cystic fibrosis.
An investor consortium led by British Arix Bioscience plc has put £13.4m into the Australian Pharmaxis Ltd, which develops fibrosis inhibitors based on its amine oxidase discovery platform.